Related Experiment Video
Updated: Aug 18, 2026
Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging
Published on: April 6, 2014
Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998
T K McIntosh1, M Juhler, T Wieloch
1Department of Neurosurgery, University of Pennsylvania, Philadelphia 19104-6316, USA.
Abstract:
The mechanisms underlying secondary or delayed cell death following traumatic brain injury are poorly understood. Recent evidence from experimental models suggests that widespread neuronal loss is progressive and continues in selectively vulnerable brain regions for months to years after the initial insult. The mechanisms underlying delayed cell death are believed to result, in part, from the release or activation of endogenous "autodestructive" pathways induced by the traumatic injury. The development of sophisticated neurochemical, histopathological and molecular techniques to study animal models of TBI have enabled researchers to begin to explore the cellular and genomic pathways that mediate cell damage and death. This new knowledge has stimulated the development of novel therapeutic agents designed to modify gene expression, synthesis, release, receptor or functional activity of these pathological factors with subsequent attenuation of cellular damage and improvement in behavioral function. This article represents a compendium of recent studies suggesting that modification of post-traumatic neurochemical and cellular events with targeted pharmacotherapy can promote functional recovery following traumatic injury to the central nervous system.
Insights
Delayed cell death after traumatic brain injury (TBI) involves autodestructive pathways. Targeted pharmacotherapy shows promise in promoting functional recovery by modifying these post-TBI events.
Area of Science:
- Neuroscience
- Pathology
- Pharmacology
Background:
- Secondary or delayed cell death following traumatic brain injury (TBI) is not well understood.
- Neuronal loss can be progressive for months to years after the initial insult.
- Delayed cell death is linked to endogenous autodestructive pathways activated by TBI.
Purpose of the Study:
- To explore cellular and genomic pathways mediating cell damage and death after TBI.
- To review novel therapeutic agents targeting pathological factors in TBI.
- To assess the potential of pharmacotherapy for functional recovery after central nervous system injury.
Main Methods:
- Utilizing advanced neurochemical, histopathological, and molecular techniques in animal models of TBI.
- Investigating cellular and genomic pathways involved in TBI-induced cell death.
- Compiling recent studies on therapeutic interventions for TBI.
Main Results:
- Sophisticated techniques enable exploration of TBI-related cell damage pathways.
- Novel therapeutics aim to modify gene expression, synthesis, release, or receptor activity of pathological factors.
- Targeted pharmacotherapy can attenuate cellular damage and improve behavioral function.
Conclusions:
- Modification of post-traumatic neurochemical and cellular events is crucial.
- Targeted pharmacotherapy holds potential for promoting functional recovery after TBI.
- Understanding delayed cell death mechanisms is key to developing effective TBI treatments.
